CBRX Key Stats
- COLUMBIA LABORATORIES INC Files SEC form 8-K, Financial Statements and Exhibits May 9
- Q1 2013 Columbia Laboratories Earnings Release - Before Market Open May 9
- Columbia Laboratories, Inc. (CBRX) Misses Q1 EPS by 2c Street Insider May 9
- Columbia Laboratories Reports First Quarter 2013 Financial Results Business Wire May 9
- COLUMBIA LABORATORIES INC Files SEC form 10-Q, Quarterly Report May 8
- Speculative Bio Stocks For Investors May 8
- COLUMBIA LABORATORIES INC Files SEC form 8-K, Submission of Matters to a Vote of... May 3
- COLUMBIA LABORATORIES INC Files SEC form 8-K, Submission of Matters to a Vote of... May 2
- Columbia Laboratories to Discuss First Quarter 2013 Financial Results on May 9 C... Apr 25
- COLUMBIA LABORATORIES INC Files SEC form 8-K, Notice of Delisting or Failure to ... Apr 24
CBRX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Columbia Laboratories is down 4.62% over the last year vs S&P 500 Total Return up 30.43%, Warner Chilcott up 35.78%, and SciClone Pharmaceuticals down 18.09%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for CBRX
Pro Report PDF for CBRX
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CBRX Pro Report PDF
Pro Strategies Featuring CBRX
Did Columbia Laboratories make it into our Pro Portfolio Strategies?